Focal lung infiltrate complicating PD-1 inhibitor use: A new pattern of drug-associated lung toxicity?
Authors:
Open Access
- 8 September 2016
- journal article
- case report
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 19, 118-120
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Cancer immunotherapy: the beginning of the end of cancer?BMC Medicine, 2016
- Organizing Pneumonia Induced by Nivolumab in a Patient with Metastatic MelanomaJournal of Thoracic Oncology, 2016
- Programmed death 1 immune checkpoint inhibitors.2015
- Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysisExpert Opinion on Drug Safety, 2015
- Anti–PD-1–Related Pneumonitis during Cancer ImmunotherapyNew England Journal of Medicine, 2015
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2015
- Programmed cell death ligand 2 regulates TH9 differentiation and induction of chronic airway hyperreactivityJournal of Allergy and Clinical Immunology, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directionsMucosal Immunology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009